v3.26.1
Segment, Geographic and Other Revenue Information - Schedule of Significant Biopharma Segment Expenses (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Segment Reporting Information [Line Items]    
Revenues: $ 14,451 $ 13,715
Cost of sales [1] 3,548 2,845
Selling, informational and administrative expenses [1] 2,961 3,031
Research and development expenses [1] 2,490 2,203
Acquired in-process research and development expenses 137 9
Other (income)/deductions––net 861 953
Income from continuing operations before provision/(benefit) for taxes on income [2] 3,170 2,785
Biopharma [Member]    
Segment Reporting Information [Line Items]    
Revenues: [3] 14,161 13,441
Cost of sales 3,034 2,314
Selling, informational and administrative expenses 2,131 2,186
Research and development expenses 2,137 1,941
Acquired in-process research and development expenses 137 9
Other (income)/deductions––net (116) (78)
Income from continuing operations before provision/(benefit) for taxes on income $ 6,838 $ 7,069
[1] Exclusive of amortization of intangible assets.
[2] Income from continuing operations before provision/(benefit) for taxes on income. Effective in the third quarter of 2025, certain expenses for corporate affairs, which were previously reported in the operating results of corporate enabling functions, are reported in the operating results of our Biopharma reportable segment. In connection with this reporting change, we reclassified Selling, informational and administrative expenses of approximately $36 million in the first quarter of 2025 from Other business activities to Biopharma to conform to the current period presentation.
[3] In the first quarter of 2026, we made changes in our commercial structure, which included the transition of certain off-patent branded and generic sterile injectables and biosimilars primarily from the Specialty Care and Oncology product portfolios to a new Hospital and Biosimilars product portfolio within our Biopharma reportable segment. See Note 13A above. We reclassified prior period amounts to conform to the current period presentation